Alpha-Synuclein Protein Aggregates, CSF

Label Mnemonic: ASYNC
Epic code: LAB9893
Downtime form: Doctor/Provider Orders - Pathology Core and Specialty Care Nursery
Commercial Mailout Laboratory
6240-8 RCP
356-8593
Specimen(s):
CSF

Discard first 1 to 2 mL of CSF. Collect 1mL CSF directly into sterile tube.

Collection Medium:
CSF collection kit
Minimum:

0.3 mL CSF

Testing Schedule:

TAT 15–18 days

Comments:

Detection of alpha-synuclein aggregates in cerebrospinal fluid is consistent with the presence of a synucleinopathy (eg, Parkinson disease, dementia with Lewy bodies, Alzheimer disease with Lewy body pathology, and multiple system atrophy).

 

Results must be interpreted in conjunction with other patient clinical information.

 

Performing Laboratory:

Amprion Inc. (CLIA Number: 05D2209417)

  1. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology. 2016;86(6):566-576. doi:10.1212/WNL.0000000000002350
  2. Rizzo G, Arcuti S, Copetti M, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(4):358-366. doi:10.1136/jnnp-2017-316844
  3. Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord. 2022;37(6):1131-1148. doi:10.1002/mds.29005
  4. Plastini MJ, Abdelnour C, Young CB, et al. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. Ann Clin Transl Neurol. 2024;11(5):1197-1210. doi:10.1002/acn3.52034
  5. Tosun D, Hausle Z, Iwaki H, et al. A cross-sectional study of alpha-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function. Alzheimers Dement. 2024;20(8):5114-5131. doi:10.1002/alz.13858
Methodology:

Seed amplification assay

CPT Code:
0393U